BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

356 related articles for article (PubMed ID: 31814296)

  • 1. Surgical treatment following neoadjuvant chemoradiotherapy in locally advanced rectal cancer.
    Huang MY; Huang CW; Wang JY
    Kaohsiung J Med Sci; 2020 Mar; 36(3):152-159. PubMed ID: 31814296
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Comparison of long-term efficacy between watch and wait strategy and total mesorectal excision in locally advanced rectal cancer patients with clinical complete response after neoadjuvant therapy].
    Wang XH; Zhou CJ; Zhang S; Wang QX; Xiao WW; Ding PR; Chen G; Pan ZZ; Zeng ZF; Gao YH
    Zhonghua Wei Chang Wai Ke Za Zhi; 2020 Mar; 23(3):266-273. PubMed ID: 32192306
    [No Abstract]   [Full Text] [Related]  

  • 3. [Comparison of short-term efficacy and perioperative safety between neoadjuvant therapy and total neoadjuvant therapy in patients with locally advanced rectal cancer].
    Zhai ZW; Zhang KN; Wang C; Han JG; Ma HC; Wei GH; Yang Y; Wang ZJ
    Zhonghua Wei Chang Wai Ke Za Zhi; 2020 Mar; 23(3):274-280. PubMed ID: 32192307
    [No Abstract]   [Full Text] [Related]  

  • 4. [Rectum-preserving surgery after consolidation neoadjuvant therapy or totally neoadjuvant therapy for low rectal cancer: a preliminary report].
    Huang Y; Huang SH; Chi P; Wang XJ; Lin HM; Lu XR; Ye DX; Lin Y; Deng Y
    Zhonghua Wei Chang Wai Ke Za Zhi; 2020 Mar; 23(3):281-288. PubMed ID: 32192308
    [No Abstract]   [Full Text] [Related]  

  • 5. ["Watch and wait" strategy after neoadjuvant therapy for rectal cancer: status survey of perceptions, attitudes and treatment selection in Chinese surgeons].
    Sun TT; Wang L; Yao YF; Peng YF; Zhao J; Zhan TC; Leng JH; Wang HY; Chen N; Chen PJ; Li YJ; Zhang X; Liu XZ; Zhang Y; Wu AW
    Zhonghua Wei Chang Wai Ke Za Zhi; 2019 Jun; 22(6):550-559. PubMed ID: 31238634
    [No Abstract]   [Full Text] [Related]  

  • 6. Is neoadjuvant chemoradiotherapy always necessary for mid/high local advanced rectal cancer: A comparative analysis after propensity score matching.
    Zhang Y; Sun Y; Xu Z; Chi P; Lu X
    Eur J Surg Oncol; 2017 Aug; 43(8):1440-1446. PubMed ID: 28502421
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Systemic Chemotherapy as Salvage Treatment for Locally Advanced Rectal Cancer Patients Who Fail to Respond to Standard Neoadjuvant Chemoradiotherapy.
    Sclafani F; Brown G; Cunningham D; Rao S; Tekkis P; Tait D; Morano F; Baratelli C; Kalaitzaki E; Rasheed S; Watkins D; Starling N; Wotherspoon A; Chau I
    Oncologist; 2017 Jun; 22(6):728-736. PubMed ID: 28476941
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Worse treatment response to neoadjuvant chemoradiotherapy in young patients with locally advanced rectal cancer.
    Zhang Y; Yan L; Wu Y; Xu M; Liu X; Guan G
    BMC Cancer; 2020 Sep; 20(1):854. PubMed ID: 32891131
    [TBL] [Abstract][Full Text] [Related]  

  • 9. GOLPH3 overexpression correlates with poor response to neoadjuvant therapy and prognosis in locally advanced rectal cancer.
    Zhu K; Zhao Q; Yue J; Shi P; Yan H; Xu X; Wang R
    Oncotarget; 2016 Oct; 7(42):68328-68338. PubMed ID: 27634904
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of body mass index on treatment outcome of neoadjuvant chemoradiotherapy in locally advanced rectal cancer.
    Sun Y; Xu Z; Lin H; Lu X; Huang Y; Huang S; Wang X; Chi P
    Eur J Surg Oncol; 2017 Oct; 43(10):1828-1834. PubMed ID: 28888798
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Analysis on efficacy and safety of total neoadjuvant therapy in patients with locally advanced rectal cancer with high risk factors].
    Ouyang GL; Meng WJ; Shu P; Deng XB; Wu B; Jiang D; Zhuang H; Shen YL; Zhou ZG; Wang ZQ; Wang X
    Zhonghua Wei Chang Wai Ke Za Zhi; 2019 Apr; 22(4):349-356. PubMed ID: 31054549
    [No Abstract]   [Full Text] [Related]  

  • 12. MRI T2-weighted sequences-based texture analysis (TA) as a predictor of response to neoadjuvant chemo-radiotherapy (nCRT) in patients with locally advanced rectal cancer (LARC).
    Crimì F; Capelli G; Spolverato G; Bao QR; Florio A; Milite Rossi S; Cecchin D; Albertoni L; Campi C; Pucciarelli S; Stramare R
    Radiol Med; 2020 Dec; 125(12):1216-1224. PubMed ID: 32410063
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Worse prognosis in young patients with locally advanced rectal cancer following neoadjuvant chemoradiotherapy: A comparative study.
    Zhang Y; Wang Y; Liu X; Chen B; Zhuang J; Li S; Yang Y; Su Y; Guan G
    Medicine (Baltimore); 2020 Aug; 99(35):e21304. PubMed ID: 32871861
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Meta-analysis of Total Neoadjuvant Therapies Combining Chemoradiotherapy with Induction or Consolidated Chemotherapy for Locally Advanced Rectal Cancer.
    Nov P; Du K; Huang Z; Li Y; Gong M; Liu X; Li C; Li L; Wang D; Zhang Y; Wang C; Li J
    J Gastrointest Cancer; 2023 Sep; 54(3):693-702. PubMed ID: 36243897
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic significance of carcinoembryonic antigen combined with carbohydrate antigen 19-9 following neoadjuvant chemoradiotherapy in patients with locally advanced rectal cancer.
    Zheng Z; Wang X; Lu X; Huang Y; Chi P
    Colorectal Dis; 2021 Sep; 23(9):2320-2330. PubMed ID: 33900006
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Application value of colonoscopic assessment in "watch and wait" strategy for mid-lower rectal cancer after neoadjuvant chemoradiotherapy].
    Li SJ; Wang L; Zhang XY; Li YH; Li ZW; Wu Q; Sun YS; Wu AW
    Zhonghua Wei Chang Wai Ke Za Zhi; 2019 Jul; 22(7):648-655. PubMed ID: 31302963
    [No Abstract]   [Full Text] [Related]  

  • 17. [Outcome of watch and wait strategy or organ preservation for rectal cancer following neoadjuvant chemoradiotherapy: report of 35 cases from a single cancer center].
    Wu A; Wang L; Du C; Peng Y; Yao Y; Zhao J; Zhan T; Cai Y; Li Y; Sun Y; Ji J
    Zhonghua Wei Chang Wai Ke Za Zhi; 2017 Apr; 20(4):417-424. PubMed ID: 28440523
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rationale and design of a prospective, multicenter, phase II clinical trial of safety and efficacy evaluation of long course neoadjuvant chemoradiotherapy plus tislelizumab followed by total mesorectal excision for locally advanced rectal cancer (NCRT-PD1-LARC trial).
    Yang Z; Zhang X; Zhang J; Gao J; Bai Z; Deng W; Chen G; An Y; Liu Y; Wei Q; Han J; Li A; Liu G; Sun Y; Kong D; Yao H; Zhang Z
    BMC Cancer; 2022 Apr; 22(1):462. PubMed ID: 35477432
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metformin: A Promising Radiosensitizer in Neoadjuvant Rectal Cancer Treatment.
    Georgopoulos NS; Tolia M; Mauri D; Kamposioras K; Charalampakis N; Tsoukalas N; Gkantaifi A
    Rev Recent Clin Trials; 2023; 18(3):172-180. PubMed ID: 37132307
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An integrated multiomics analysis of rectal cancer patients identified POU2F3 as a putative druggable target and entinostat as a cytotoxic enhancer of 5-fluorouracil.
    D'Angelo E; Pastrello C; Biccari A; Marangio A; Sensi F; Crotti S; Fassan M; Jurisica I; Pucciarelli S; Agostini M
    Int J Cancer; 2023 Jul; 153(2):437-449. PubMed ID: 36815540
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.